21st Jun 2018 09:11
PRESS RELEASE
FOR IMMEDIATE RELEASE
Exercise of options
London, UK - 21 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that it has issued 47,000 new ordinary shares of 1p each in the Company ('New Ordinary Shares'). The New Ordinary Shares have been allotted pursuant to exercise of share options awarded to two individuals under the Ergomed plc Long Term Incentive Plan.
Application has been made to the London Stock Exchange for 47,000 Ordinary Shares to be admitted to trading on AIM ('Admission'). It is expected that Admission will occur at 8:00 a.m. on 22 June 2018. The Ordinary Shares will rank pari passu with the existing ordinary shares in the Company.
Following Admission, the Company's enlarged issued share capital and total number of voting rights will be 44,858,602 Ordinary Shares.
ENDS
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 503 205 | |
Stephen Stamp (Chief Executive Officer) | ||
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 | |
Michael Meade / Freddie Barnfield (Nominated Adviser) | ||
James Black (Joint Broker) | ||
N+1 Singer | Tel: +44 (0) 20 7496 3000 | |
Aubrey Powel (Joint Broker) | ||
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 | |
Chris Gardner / Mary-Jane Elliott Ivar Milligan / Philippa Gardner | ||
MC Services - for Continental European enquiries | Tel: +49 211 5292 5222 | |
Anne Hennecke | ||
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
Related Shares:
ERGO.L